Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Agitation and Aggression in Alzheimer's Disease
2016-001127-32Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD), agitation and Aggression (not a disease; see rationale) comparing Pimavanserin with Placebo (2 arms). Primary endpoint: Change in NPI-C agitation and aggression score. Started Jun 2016; status: completed.
02
Drugs
pimavanserin
03
Conditions
Alzheimer's disease (AD)agitationAggression (not a disease; see rationale)
Beyond the preview
Go deeper on 2016-001127-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001127-32.